Overactive Bladder (OAB)
Conditions
Keywords
anticholinergic burden, anticholinergic, overactive bladder
Brief summary
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
Interventions
OTHERNon-Interventional
Overview of anticholinergic burden, rather than to evaluate specific drugs
Sponsors
Astellas Pharma Singapore Pte. Ltd.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have at least one dispensing of any medication between January 22, 2016 and December 31, 2016. Inclusion Criteria for Korea: * Have at least one dispensing of any medication between January 1st, 2016 and December 31, 2016. * Participant was diagnosed with OAB (ICD-10 N32.8, N31.0, N31.1, N31.2, N31.8, N31.9, N32.9, N39.8 and N39.40) at index date. * Participant did not have dispensing record of an OAB medication during the washout period (6 months prior to the index date).
Exclusion criteria
* Participants who do not have a complete year of data availability in the database prior to index date. * Have record of hospitalization on the index date.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anticholinergic Cognitive Burden (ACB) score | 100 days | ACB will be calculated based on methodology from Campbell et al (2016). Sum (Drug A #days prescribed X ACB scale score) + (Drug B #days prescribed X ACB scale score) + (Drug X…)/Number of days with any medication prescribed. The cumulative score has a range from 0 to infinity, with higher values indicating a higher cumulative anticholinergic burden of the patient. |
| Korea Specific: Percentage of Participants With any Listed Anticholinergic Use | 100 days | This will be calculated as number of participants with any listed anticholinergics use divided by number of participants fulfilling the general eligibility criteria of the study (in each study dataset) multiplied by 100. |
| Korea Specific: Percentage of Participants With Strong Anticholinergic Use | 100 days | This will be calculated as number of participants with strong anticholinergics use divided by number of participants fulfilling the general eligibility criteria of the study (in each study dataset) multiplied by 100. |
| Korea Specific: Number of Anticholinergics Dispensed per Participants | 100 days | This will be calculated as total number of anticholinergics dispensed divided by number of participants fulfilling the general eligibility criteria of the study (in each study dataset) multiplied by 100. |
| Korea Specific: Attribution Proportion of OAB medications to total ACB in OAB Cohort | 100 days | Attribution proportion of OAB medication to total ACB will be calculated as the ratio between the sum over all OAB patients of the ACB scores of each OAB medication multiplied by the number of days supply in the numerator and the sum over all OAB patients of the ACB scores of each antimuscarinic medication multiplied by the number of days supply in the denominator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median percentage of ACB score derived from overactive bladder (OAB) treatment(s) in total ACB score | 100 days | The attribution of antimuscarinics for OAB treatment to entire anticholinergic exposures in OAB patients. |
Countries
Australia, South Korea
Outcome results
None listed